This inventor holds 2 USPTO granted patents. Top assignee: Eberhard Karls Universitaet Tuebingen Medizinische Fakultaet. Active years: 2021-2026.
Company Filing History:
Years Active: 2021-2026
Title: Sven Nahnsen: Innovator in Antiviral Immunotherapy
Introduction
Sven Nahnsen is a notable inventor based in Tuebingen, Germany. He has made significant contributions to the field of antiviral immunotherapy. His work focuses on developing innovative solutions for the treatment and prevention of viral infections.
Latest Patents
Sven Nahnsen holds a patent for "Antiviral immunotherapy by membrane receptor ligation." This invention relates to a cytotoxic agent designed for the prophylaxis and treatment of viral infections. The agent selectively binds to a membrane receptor of virus-infected T lymphocytes. The patent also includes a pharmaceutical composition containing this cytotoxic agent, methods for finding such agents, and the use of the membrane receptor for diagnosing viral infections. He has 1 patent to his name.
Career Highlights
Nahnsen is affiliated with the Eberhard Karls University Tuebingen, specifically within the Faculty of Medicine. His research and innovations have positioned him as a key figure in the medical community, particularly in the area of immunotherapy.
Collaborations
Sven has collaborated with notable colleagues, including Michael Schindler and Marius Codrea. These partnerships have enhanced his research efforts and contributed to the advancement of antiviral therapies.
Conclusion
Sven Nahnsen's work in antiviral immunotherapy represents a significant advancement in medical science. His innovative approach to treating viral infections showcases the potential of targeted therapies in improving patient outcomes.